Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
[PMID: 34954832] PubMed record related to this compound for laboratory literature review
The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes)
Participants aged 1875 years with moderate to severe UC (MS 6, RBS 1, MES 2) who had inadequate response to conventional therapies including corticosteroids, immunosuppressants, TNF antagonists, anti-integrin inhibitors, JAK inhibitors, or anti-IL-12/IL-23 inhibitors were eligible for inclusion
Glucagon-like peptide-1 receptor agonists and hepatocellular carcinoma prevention: a meta-analysis and clinical decision framework
& Schwartz, C
US$ 23.34
US$ 23.20
US$ 25.72
